Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ties Brisdelle Approval To Unmet Need For Hormone-Free Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

In an NEJM perspective piece, agency reviewers explain why they believed Noven’s paroxetine for treating hot flashes should come to market despite only “modest” efficacy and an advisory committee’s overwhelming recommendation against approval.

Advertisement

Related Content

Placebo Effect Raises Questions About Clinical Value For Depomed, Noven Hot Flash Treatments
Gabapentin Cannot Navigate Efficacy Hurdles At Advisory Committee
Tighter REMS For Zohydro ER Still Insufficient For FDA Advisory Panel
“Creative” FDA Clears Avastin For First-Line Breast Cancer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS077292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel